Therapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients

Therapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients

Abstract Gene targeting constitutes a new step in the development of gene therapy for inherited diseases. Although previous studies have shown the feasibility of editing fibroblasts from Fanconi anemia (FA) patients, here we aimed at conducting therapeutic gene editing in clinically relevant cells,...

Full description

Saved in:
Bibliographic Details
Main Authors: Begoña Diez, Pietro Genovese, Francisco J Roman‐Rodriguez, Lara Alvarez, Giulia Schiroli, Laura Ugalde, Sandra Rodriguez‐Perales, Julian Sevilla, Cristina Diaz de Heredia, Michael C Holmes, Angelo Lombardo, Luigi Naldini, Juan Antonio Bueren, Paula Rio
Format: Article
Language:English
Published: Springer Nature 2017-09-01
Series:EMBO Molecular Medicine
Subjects:
CD34+ cells
Fanconi anemia
gene editing
hematopoietic stem and progenitor cells
zinc finger nucleases
Online Access:https://doi.org/10.15252/emmm.201707540
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Gene targeting constitutes a new step in the development of gene therapy for inherited diseases. Although previous studies have shown the feasibility of editing fibroblasts from Fanconi anemia (FA) patients, here we aimed at conducting therapeutic gene editing in clinically relevant cells, such as hematopoietic stem cells (HSCs). In our first experiments, we showed that zinc finger nuclease (ZFN)‐mediated insertion of a non‐therapeutic EGFP‐reporter donor in the AAVS1 “safe harbor” locus of FA‐A lymphoblastic cell lines (LCLs), indicating that FANCA is not essential for the editing of human cells. When the same approach was conducted with therapeutic FANCA donors, an efficient phenotypic correction of FA‐A LCLs was obtained. Using primary cord blood CD34+ cells from healthy donors, gene targeting was confirmed not only in in vitro cultured cells, but also in hematopoietic precursors responsible for the repopulation of primary and secondary immunodeficient mice. Moreover, when similar experiments were conducted with mobilized peripheral blood CD34+ cells from FA‐A patients, we could demonstrate for the first time that gene targeting in primary hematopoietic precursors from FA patients is feasible and compatible with the phenotypic correction of these clinically relevant cells.
ISSN:1757-4676
1757-4684

Similar Items